CPSC Recall in 2021: Genentech Recalls Prescription Drug Evrysdi Due to Failure to Meet Child Resistant Packaging Requirements; Risk of Drug Exposure through Eye or Skin Absorption (Recall Alert)

Updated on January 18, 2026.

See the recall details below. You can also see similar information for other consumer product recalls in 2021.

Data Source: CPSC.
Recall Number: 21-729
Date: March 18, 2021
Product Name: Evrysdi™ (risdiplam)
Recall Description:

This recall involves bottles of the prescription drug Evrysdi, a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 months of age and older.  The recalled 100 mL amber bottles have “Evrysdi (risdiplam) for oral solution,” the dosage and “NDC 20242-175-07” on the front of the bottle labels.

Hazard Description:

The bottles containing the prescription drug can leak due to a fit issue between the press-in bottle adapter and bottleneck.  If the bottle is leaking, there is a risk of drug exposure by contact with skin or eyes.  Prescription drugs must be in child resistant packaging that prevents children from gaining access to the contents as required by the Poison Prevention Packaging Act (PPPA).

Consumer Action:

Remedy Type:

Replace

Units: About 14,000
Incidents:

Genentech has received 26 reports of leaking bottles.  No injuries have been reported.

Sold At:

Select specialty pharmacies nationwide as a prescribed medicine from August 2020 through the present.  The price of the medication varies based on health insurance terms and other factors.

Manufactured In:

Switzerland